Skip to content
drillr.ai
Sign up

MNKD

MannKind Corporation

NASDAQ · Healthcare · Biotechnology · US

$4.06
+2.53%
Ask drillr

  • Aug 5, 2026, 20:01 UTC

    MannKind launched the pediatric indication of Afrezza following FDA approval.

    Source:

  • Aug 5, 2026, 20:01 UTC

    MannKind reported positive Phase 1b data for nintedanib DPI in IPF patients, supporting continued Phase 2 advancement.

    Source:

  • Aug 5, 2026, 20:01 UTC

    MannKind received approval for FUROSCIX ReadyFlow autoinjector for treatment of edema in heart failure and chronic kidney disease.

    Source:

  • Aug 5, 2026, 00:00 UTC

    MannKind Corp reported Q2 2026 total revenue of $109.4 million, up 43% year-over-year, with a net loss of $19.1 million, driven by strong sales of Afrezza and Furoscix.

    Source:

  • Jul 29, 2026, 10:30 UTC

    MannKind Corporation announced positive Phase 1b INFLO-1 trial results for its Nintedanib DPI product, demonstrating safety and tolerability in patients with idiopathic pulmonary fibrosis and clinical validation of its DPI technology.

    Source:

  • Jul 24, 2026, 10:35 UTC

    MannKind Corporation announced a $50 million private placement of securities.

    Source:

  • Jul 24, 2026, 10:30 UTC

    MannKind Corporation received FDA approval for Furoscix ReadyFlow, an autoinjector delivering IV-equivalent diuretic therapy for edema in adults with heart failure or chronic kidney disease.

    Source:

  • Jun 23, 2026, 13:00 UTC

    MannKind Corporation was awarded a Breakthrough T1D grant to support the INHALE-1ST pediatric trial of Afrezza in youth with newly-diagnosed type 1 diabetes.

    Source:

  • Jun 5, 2026, 23:35 UTC

    MannKind Corporation announced new clinical and real-world data for Afrezza and FUROSCIX to be presented at the American Diabetes Association 2026 conference.

    Source:

  • May 31, 2026, 03:07 UTC

    MannKind received FDA approval for Afrezza in pediatric patients with diabetes ages 6 and older.

    Source: